Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guna-NT4
- Development stage
- Unknown
- Lead developer
- Guna
- Modality
- Small Molecules, Hormones & Growth Factors → Recombinant Proteins and Enzymes, Hormonal Peptides → Native Peptides → Peptides, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
Guna-NT4 is a low-dose medicinal formulation of Neurotrophin-4 (NT4) developed by Guna S.p.a. for the treatment of retinal atrophy and other degenerative retinal conditions. Utilizing Guna's proprietary Sequential Kinetic Activation (SKA) technology, the formulation delivers NT4 at physiological low doses (homeopathic dilutions) intended to provide neurotrophic support to retinal neurons. The mechanism of action involves the activation of the Tropomyosin receptor kinase B (TrkB), which promotes cell survival and potentially improves visual function by slowing the progression of retinal cell death. This approach aims to leverage the signaling benefits of neurotrophins while avoiding the receptor downregulation often associated with high-dose exogenous growth factor administration. The drug has been evaluated in Phase 2 clinical studies, including retrospective analyses of patients with retinal atrophy.
- Other names
- low-dose neurotrophin-4Guna-Neurotrophin-4Guna-Neurotrophin4Guna-Neurotrophin 4
02
Targets
NTRK2 (Tropomyosin-related kinase receptor type B)
Beyond the preview
Go deeper on Guna-NT4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guna-NT4.